Recursion Technologies Competitors

Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990 and is engaged with customers and collaborators in more than 70 countries. We welcome you to visit our blog at www.extrapolations.com. Stay Alert: Avoid Recruitment Scams Across industries, cybercriminals are posing as company recruiters using fake job postings and employment offers. Please stay vigilant: - Never provide personal/financial information or payment to anyone claiming to offer a job opportunity - Always verify job postings through official company websites or direct contacts - Be cautious of unusual communication methods or overly quick offers

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.

Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.